By Fineline Cube 
German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology specialist LEO Pharma A/S for the commercialization and further development of its biologic drug Spevigo (spesolimab). This strategic move leverages LEO Pharma’s global dermatology commercial platform to enhance patient access and disease awareness.
Spevigo’s Approved Indications
Spevigo, a first-in-class monoclonal antibody (mAb) targeting the interleukin-36 receptor (IL-36R), is approved in over 40 countries and regions, including the US, Japan, China, and the European Union. It is currently indicated for the treatment of generalized pustular psoriasis (GPP) attacks.
Collaboration Details
Under the agreement, LEO Pharma will assume responsibility for the commercialization and further development of Spevigo. The collaboration extends beyond GPP, with plans to explore the potential of spesolimab in other IL-36-mediated dermatological conditions where significant unmet medical needs exist.
Financial Terms
The transaction is expected to close in the second half of 2025. Boehringer Ingelheim will receive an upfront payment of EUR 90 million (USD 105 million) from LEO Pharma, along with additional milestone payments and tiered royalties.-Fineline Info & Tech